RN
$7.98
+0.37
(+4.86%)
As of Oct 20, 2026, 7:05 PM EDT
Price history
Atrium Therapeutics Inc (RNA) is trading up at $7.98 (+4.86%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: June 12, 2020 · $18.00 offering · NASDAQ · View IPO details →
Atrium Therapeutics Inc revenue & net income history
RevenueNet incomeNet margin (right axis, %)
| Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $1.57M | $3.85M | $19.6M | $3.00M |
| Growth (year over year) | — | — | +1148.3% | −21.9% |
| Operating income | −$7.45M | −$12.9M | −$17.3M | −$22.6M |
| Operating margin | −473.7% | −334.4% | −88.0% | −752.9% |
| Net income | −$7.45M | −$12.9M | −$16.6M | −$20.2M |
| Net margin | −473.6% | −334.8% | −84.7% | −672.0% |
| EPS (diluted) | −$0.44 | −$0.75 | −$0.97 | −$1.18 |
| Balance sheet | ||||
| Cash and equivalents | $0 | $0 | $267.8M | $72.3M |
| Total assets | — | — | $292.4M | $280.5M |
| Total liabilities | — | — | $58.3M | $65.9M |
| Shareholders' equity | −$56.3M | −$56.2M | $234.1M | $214.6M |
| Cash flow | ||||
| Operating cash flow | −$11.1M | −$11.9M | −$31.1M | −$3.93M |
| Capital expenditure | $0 | $266.0K | $2.10M | $36.0K |
| Free cash flow | −$11.1M | −$12.2M | −$33.2M | −$3.96M |
From Atrium Therapeutics Inc's 10-Q filings with the SEC. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Filings on SEC EDGAR →
About Atrium Therapeutics Inc
- Headquarters
- San Diego, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International